SV7 Plus Growth FundFiled to raise in 2024, with no closing reported yet.
2024
$60M
$0
0
Dementia Discovery Fund 2
March 2022
$350M
$202M
16
SV7 Growth Fund Strategic PartnersFiled to raise in 2022, with no closing reported yet.
2022
Indefinite
$0
0
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
Who at SV Life Sciences can lead a round?
19 named
19 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Climate & energy3 · 4%
Enterprise software2 · 3%
Food & agriculture2 · 3%
Robotics & hardware2 · 3%
Aerospace & defense1 · 1%
AI & machine learning1 · 1%
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of SV Life Sciences’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
A shared board seat: a company where filings name a SV Life Sciences partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
